Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A
monoclonal antibody under investigation for the treatment of variouscancers .
Etymologies
from Wiktionary, Creative Commons Attribution/Share-Alike License
Support
Help support Wordnik (and make this page ad-free) by adopting the word figitumumab.
Examples
-
Pfizer Inc. said it ended a Phase III trial for its experimental lung-cancer drug called figitumumab.
Pfizer Disappointed in Study Results for Two Drugs John Kell 2010
-
The company also said it would continue to study figitumumab in clinical trials for the potential treatment of prostate, breast and lung cancers.
Pfizer Disappointed in Study Results for Two Drugs John Kell 2010
-
In the latest discontinuation, Pfizer was examining the effects of a compound with figitumumab as a second -/third-line treatment in patients with previously treated advanced non-small cell lung cancer.
Pfizer Disappointed in Study Results for Two Drugs John Kell 2010
-
Pfizer Inc. said it ended a Phase III trial for its experimental lung-cancer drug called figitumumab.
Pfizer Disappointed in Study Results for Two Drugs John Kell 2010
-
The company also said it would continue to study figitumumab in clinical trials for the potential treatment of prostate, breast and lung cancers.
Pfizer Disappointed in Study Results for Two Drugs John Kell 2010
-
In the latest discontinuation, Pfizer was examining the effects of a compound with figitumumab as a second -/third-line treatment in patients with previously treated advanced non-small cell lung cancer.
Pfizer Disappointed in Study Results for Two Drugs John Kell 2010
-
Pfizer Inc. said it ended a Phase III trial for its experimental lung-cancer drug called figitumumab.
Pfizer Disappointed in Study Results for Two Drugs John Kell 2010
-
The company also said it would continue to study figitumumab in clinical trials for the potential treatment of prostate, breast and lung cancers.
Pfizer Disappointed in Study Results for Two Drugs John Kell 2010
-
In the latest discontinuation, Pfizer was examining the effects of a compound with figitumumab as a second -/third-line treatment in patients with previously treated advanced non-small cell lung cancer.
Pfizer Disappointed in Study Results for Two Drugs John Kell 2010
-
Pfizer ends study on potential lung cancer drugNEW YORK - Pfizer Inc. said Thursday it discontinued a late-stage study of the drug candidate figitumumab in patients with late-stage lung cancer, citing a lack of effectiveness.
Gaea Times (by Simple Thoughts) Breaking News and incisive views 24/7 2010
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.